BioMarin Pharmaceutical Inc.
BMRN
$66.03
$0.961.48%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -88.90% | -48.70% | -18.26% | 61.47% | 156.15% |
| Total Depreciation and Amortization | 74.87% | -27.04% | -25.17% | -17.01% | -21.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 116.86% | 142.67% | 160.65% | 134.70% | 63.19% |
| Change in Net Operating Assets | 79.34% | 18.53% | -35.70% | 7.64% | -27.50% |
| Cash from Operations | 11.78% | 24.85% | 44.54% | 120.40% | 133.16% |
| Capital Expenditure | -65.47% | -40.88% | -20.62% | 13.67% | 26.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 690.95% | 268.58% | -111.72% | -20.33% | 43.60% |
| Cash from Investing | -24,561.88% | 177.19% | -403.49% | -5,958.02% | 156.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -30,374.43% |
| Issuance of Common Stock | -34.16% | -65.64% | -70.66% | -72.29% | -63.49% |
| Repurchase of Common Stock | 28.32% | 31.67% | 27.84% | 24.03% | 17.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,033.24% | -204.37% | 72.02% | 96.99% | -32.86% |
| Cash from Financing | 758.31% | 254.96% | 91.95% | 91.77% | -2,580.95% |
| Foreign Exchange rate Adjustments | 106.73% | -79.49% | -152.19% | 6.43% | -237.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -240.61% | 570.51% | 96.49% | 622.58% | -13.00% |